Lysosome Targeted Nanoparticle Aggregation Reverses Immunosuppressive Tumor Microenvironment for Cancer Immunotherapy
Advanced Materials · 2024-11 · 36 (47)
DOI: 10.1002/adma.202412730 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 02.10.2024. Verfasst von Yumeng Xing und 6 weiteren Autor:innen. Beteiligte Einrichtung: Research Center for Translational Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230032, P. R. China. Hauptthemen laut MEDLINE: Lysosomes, Immunotherapy, Tumor Microenvironment, Nanoparticles. Die Arbeit wurde bisher 68-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Programs of China, Natural Science Foundation of Anhui Province of China.
Abstract (Originalsprache)
Nanotechnology has proven its enormous application value in clinical practice. However, current research on nanomedicines mainly focuses on developing nanoparticles as delivery carriers to maximize the bioavailability of therapeutic agents, with little attention on exploring their potential to directly regulate physiological processes. In this study, inspired by the lysosomal swelling caused by excessive accumulation of undegraded substances, this work presents a lysosomal‐targeting aggregated nanoparticle (LTANP) for cancer treatment. By rationally engineering surface composition, properties, and interparticle interactions, LTANP achieves efficient tumor accumulation and selective targeted aggregation in lysosomes of cancer cells, leading to unrelievable lysosomal swelling, and ultimately inducing lysosomal membrane permeabilization (LMP) of cancer cells. Further analysis shows that nanoparticle aggregation‐mediated LMP can effectively trigger immunogenic cell death (ICD) by impairing autophagy‐lysosome pathway, evoking robust antitumor immune responses and reversing tumor immunogenicity from “cold” to “hot” in a melanoma model. Additionally, LTANP can combine with clinically approved programmed death ligand‐1 (PD‐L1) antibodies to further unleash T cell‐mediated antitumor immunity, significantly enhancing antitumor performance, inhibiting tumor recurrence and metastasis. This work demonstrates the potential of rationally engineered nanostructures in directly combating cancer and provides novel insights for the development of advanced nanoparticle‐based cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Center for Translational Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230032, P. R. China.
- School of Pharmacy, Anhui Medical University, Hefei, 230032, P. R. China.
- College of Chemistry and Chemical Engineering, Xiamen University, Xiamen, 361005, P. R. China.
- College of Chemistry, Nankai University, Tianjin, 300071, P. R. China.
ORCID-Profile: Qi Liu
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Programs of China
- Natural Science Foundation of Anhui Province of China
- Natural Science Research Project for Anhui Universities
- Open Project of Key Laboratory of Functional Polymer, Ministry of Education
Zitieren
APA
Xing, Y., Yang, J., Peng, A., Qian, Y., Liu, Y., Pan, P., & Liu, Q. (2024). Lysosome Targeted Nanoparticle Aggregation Reverses Immunosuppressive Tumor Microenvironment for Cancer Immunotherapy. Advanced Materials, 36(47). https://doi.org/10.1002/adma.202412730
Vancouver
Xing Y, Yang J, Peng A, Qian Y, Liu Y, Pan P, et al. Lysosome Targeted Nanoparticle Aggregation Reverses Immunosuppressive Tumor Microenvironment for Cancer Immunotherapy. Advanced Materials. 2024;36(47). doi:10.1002/adma.202412730
BibTeX
@article{Xing2024,
author = {Xing, Yumeng and Yang, Jianhui and Peng, Ao and Qian, Yujing and Liu, Yang and Pan, Pei and Liu, Qi},
title = {Lysosome Targeted Nanoparticle Aggregation Reverses Immunosuppressive Tumor Microenvironment for Cancer Immunotherapy},
journal = {Advanced Materials},
year = {2024},
volume = {36},
number = {47},
doi = {10.1002/adma.202412730}
}
EUVIMED